A multicenter double-blind, randomized, placebo-controlled, parallel-group study with three fixed doses of aripiprazole in the treatment of children and adolescents with autistic disorder (AD)

Trial Profile

A multicenter double-blind, randomized, placebo-controlled, parallel-group study with three fixed doses of aripiprazole in the treatment of children and adolescents with autistic disorder (AD)

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Nov 2013

At a glance

  • Drugs Aripiprazole (Primary)
  • Indications Autistic disorder
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Bristol-Myers Squibb; Otsuka Pharmaceutical Development & Commercialization
  • Most Recent Events

    • 21 Nov 2009 Based on data from this and another phase III study (CTP 700015397), the U.S. FDA has approved aripiprazole for the treatment of irritability associated with autistic disorder in paediatric patients (ages 6 to 17 years).
    • 01 Oct 2009 Results published in the Journal of the American Academy of Child and Adolescent Psychiatry.
    • 18 May 2009 Results presented at the 162nd Annual Meeting of the American Psychiatric Association (APA 2009).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top